SCHEMBL3737614

SCHEMBL3737614

CC(C)(CCCC(=O)OCc1ccccc1)OC(=O)NCCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.54
CPB1 P15086 1/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FOLH1 Q04609 3/20 0.43
SYK P43405 1/20 0.42
EPHX2 P34913 1/20 0.42
IDO1 P14902 1/20 0.41
TGM2 P21980 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
TPSAB1 Q15661 1/20 0.41
TPSD1 Q9BZJ3 1/20 0.41
TPSG1 Q9NRR2 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3742296 0.85 EPHX2 (0.47) HTTSYKEPHX2TGM2TPSAB1
SCHEMBL7431128 0.82 HTT (0.60) HTTLMNASMN1; SMN2SYKEPHX2
SCHEMBL3955009 0.81 SYK (0.57) HTTLMNASMN1; SMN2SYKIDO1
SCHEMBL23030235 0.81 FOLH1 (0.45) HTTFOLH1MEN1KMT2AALDH1A1
SCHEMBL4924340 0.81 HTT (0.56) HTTSYKEPHX2IDO1TGM2
SCHEMBL25448093 0.80 SYK (0.44) HTTLMNASMN1; SMN2SYKTPSAB1
SCHEMBL2417332 0.80 TPSAB1 (0.56) HTTSYKEPHX2IDO1TGM2
SCHEMBL23777326 0.80 TPSAB1 (0.56) HTTSYKEPHX2IDO1TGM2
SCHEMBL21741200 0.79 ALDH1A1 (0.45) LMNASYKEPHX2MEN1KMT2A
SCHEMBL25376237 0.78 HTT (0.55) HTTLMNASMN1; SMN2SYKEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710000-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-04-29 US disclosed
US-20100279931-A1 Insulin Derivative NOVO NORDISK A/S 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279931-A1 Insulin Derivative IAPP, INSR, GPR119 HTT 1328/4885CPB1 929/4885LMNA 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.